arXiv:2602.22822v3 Announce Type: replace Abstract: Tandem mass spectrometry (MS/MS) is central to small molecule identification, but current deep learning systems for spectrum prediction still remain difficult to evaluate and deploy in practice. While novel architectures constantly claim state-of-the-art performance, inconsistent metadata conditioning and entangled preprocessing pipelines hinder fair architectural comparisons. Besides, existing evaluations are often restricted to curated datasets, failing to capture the heterogeneity and cross-domain shifts of real-world metabolomics. Further
The proliferation of deep learning in scientific domains necessitates standardized benchmarks to ensure rigorous evaluation and foster continued progress.
A unified public benchmark for molecular mass spectrometry prediction will accelerate drug discovery, materials science, and biotechnological innovation by improving the reliability and comparability of AI models.
This benchmark introduces a consistent framework for evaluating deep learning models in molecular identification, moving beyond fragmented and inconsistent evaluation practices.
- · AI model developers in chemistry
- · Pharmaceutical companies
- · Biotechnology sector
- · Academic researchers
- · Companies relying on proprietary, non-standardized evaluation methods
- · Developers whose models underperform in a fair comparison
Improved deep learning models for molecular identification, leading to faster and more accurate analysis.
Reduced R&D costs and accelerated innovation in fields relying on small molecule analysis, such as drug discovery.
The establishment of similar unified benchmarks in other complex scientific domains, fostering a more rigorous and collaborative AI research ecosystem.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at arXiv cs.AI